Companies › PRLD
PRELUDE THERAPEUTICS INC (PRLD)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001678660 · EDGAR filings · Updated 2026-07-08
PRELUDE THERAPEUTICS INC (PRLD) has reported institutional ownership of 48.8%, with 55 institutional managers holding positions valued at $105.2M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-08 — SCHEDULE 13G filed
- 2026-06-10 — Insider transaction reported (Form 4)
- 2026-06-10 — Insider transaction reported (Form 4)
- 2026-06-10 — Insider transaction reported (Form 4)
- 2026-06-10 — Insider transaction reported (Form 4)
- 2026-06-10 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, PRELUDE THERAPEUTICS INC has 55 institutional holders and institutional ownership of 48.8%.
Insider activity
Insiders reported 6 transactions (0 buys, 0 sells) across 2 reporting insiders, with a net reported value of $0.
Data flags from SEC filings
Related companies
ACUMEN PHARMACEUTICALS INC (ABOS) · ARTIVA BIOTHERAPEUTICS INC (ARTV) · Kalaris Therapeutics Inc (KLRS) · ELECTROMED INC (ELMD) · SILENCE THERAPEUTICS PLC (SLN) · ZENTALIS PHARMACEUTICALS INC (ZNTL)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-08.